Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies

Abstract

This study aimed to evaluate the effectiveness of tamsulosin monotherapy for the treatment of ureteral stent-related symptoms (SRSs) and compare it with that of solifenacin monotherapy and combined therapy of tamsulosin and silifenacin. Randomized controlled trials (RCTs), which evaluated the effectiveness of tamsulosin for the treatment of SRSs, were searched from the databases PubMed, EMBASE and the Cochrane Library published up to November 2018. Eight RCTs involving 1087 participants were finally included in this meta-analysis. The results showed that tamsulosin monotherapy could significantly decrease the urinary symptoms [mean difference (MD) −7.56, 95% confidence interval (CI) (−11.47, −3.65), P=0.0001] and body pain [MD −5.25, 95% CI (−8.03, −2.46), P=0.0002], and improve the sexual performance [MD −1.06, 95% CI (−1.89, −0.24), P=0.01] compared with the control group. Moreover, there was no significant difference between tamsulosin monotherapy and solifenacin monotherapy in all outcomes except for significantly better sexual performance in solifenacin group [MD 0.29, 95% CI (0.06, 0.51), P=0.01]. In addition, the effectiveness of combined therapy of tamsulosin and solifenacin was not superior to that of tamsulosin monotherapy. Our study demonstrated that tamsulosin monotherapy was effective for the treatment of patients with SRSs; evident superiority could not be found for therapy of tamsulosin and solifenacin combined.

Keywords

tamsulosin / solifenacin / ureteral stent-related symptoms / meta-analysis

References

[1] ChewBH, KnudsenBE, DenstedtJD. The use of stents in contemporary urology. Curr Opin Urol, 2004, 14(2): 111-115

[2] JeongH, KwakC, LeeSE. Ureteric stenting after ureteroscopy for ureteric stones: a prospective randomized study assessing symptoms and complications. BJU Int, 2004, 93(7): 1032-1034 discussion 1034–1035

[3] ZimskindPD, FetterTR, WilkersonJL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol, 1967, 97(5): 840-844

[4] FiukJ, BaoY, CallearyJG, et al.. The use of internal stents in chronic ureteral obstruction. J Urol, 2015, 193(4): 1092-1100

[5] JoshiHB, OkekeA, NewnsN, et al.. Characterization of urinary symptoms in patients with ureteral stents. Urology, 2002, 59(4): 511-516

[6] El-NahasAR, El-AssmyAM, ShomaAM, et al.. Self-retaining ureteral stents: analysis of factors responsible for patients’discomfort. J Endourol, 2006, 20(1): 33-37

[7] ChewBH, SeitzC. Impact of ureteral stenting in ureteroscopy. Curr Opin Urol, 2016, 26(1): 76-80

[8] ZhouL, CaiX, LiH, et al.. Effects of alpha-Blockers, Antimuscarinics, or Combination Therapy in Relieving Ureteral Stent-Related Symptoms: A Meta-Analysis. J Endourol, 2015, 29(6): 650-656

[9] WangJ, ZhangX, ZhangT, et al.. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol, 2017, 35(11): 1669-1680

[10] ZhangYM, ChuP, WangWJ. PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis. Medicine, 2017, 96(7): e6098

[11] HigginsJP, AltmanDG, GotzschePC, et al.. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj, 2011, 343: d5928

[12] ParkJ, YooC, HanDH, et al.. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol, 2015, 33(11): 1833-1840

[13] El-NahasAR, TharwatM, ElsaadanyM, et al.. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol, 2016, 34(7): 963-968

[14] AbdelaalAM, Al-AdlAM, AbdelbakiSA, et al.. Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol, 2016, 14(2): 115-122

[15] SinghI, TripathyS, AgrawalV. Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol, 2014, 46(12): 2279-2283

[16] DellisAE, KeeleyFXJr, ManolasV, et al.. Role of alpha-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology, 2014, 83(1): 56-61

[17] WangCJ, HuangSW, ChangCH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res, 2009, 37(3): 147-152

[18] DamianoR, AutorinoR, De SioM, et al.. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol, 2008, 22(4): 651-656

[19] DellisAE, PapatsorisAG, KeeleyFXJr, et al.. Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study. J Endourol, 2017, 31(1): 100-109

[20] KoprowskiC, KimC, ModiPK, et al.. Ureteral Stent-Associated Pain: A Review. J Endourol, 2016, 30(7): 744-753

[21] LambAD, VowlerSL, JohnstonR, et al.. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int, 2011, 108(11): 1894-1902

[22] HeF, ManLB, LiGZ, et al.. Efficacy of alpha-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison. Drug Des Devel Ther, 2016, 10: 1783-1793

[23] LeeYJ, HuangKH, YangHJ, et al.. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis, 2013, 41(3): 247-252

[24] YanH, WangY, SunR, et al.. The Efficacy of Antimuscarinics Alone or in Combination with Alpha-Blockers for the Treatment of Ureteral Stent-Related Symptoms: A Systematic Review and Meta-Analysis. Urol Int, 2017, 99(1): 6-13

[25] JoshiHB, NewnsN, StainthorpeA, et al.. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol, 2003, 169(3): 1060-1064

[26] NavanimitkulN, LojanapiwatB. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: a randomized controlled study. J Int Med Res, 2010, 38(4): 1436-1441

[27] ShalabyE, AhmedAF, MaaroufA, et al.. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol, 2013, 2013: 752382

[28] Valiere VialeixM, PuichaudA, IraniJ. Role of tamsulosin in improving double-J ureteric stent-related symptoms. A prospective multi-center, randomized study. Prog Urol, 2014, 24(10): 620-627

[29] LimKT, KimYT, LeeTY, et al.. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol, 2011, 52(7): 485-488

[30] LiuQ, LiaoB, ZhangR, et al.. Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms - outcome from a randomized controlled trial. BMC Urol, 2016, 16(1): 66

[31] LeeSJ, YooC, OhCY, et al.. Stent Position Is More Important than alpha-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol, 2010, 51(9): 636-641